LFB Group is a biopharmaceutical group that develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases in several major therapeutic areas: immunology, intensive care and hemostasis.
LFB Group is the leading manufacturer of plasma-derived medicinal products in France and the 6th player worldwide. It is also among the leading European companies for the development of monoclonal antibodies and new-generation proteins based on biotechnologies.
With its strong research activities, LFB Group is developing a growth strategy to expand its business activities in international markets and to offer new therapeutics.
LFB is the 3rd largest laboratory supplying hospitals in France. Thanks to a wide range of 17 medicinal products, 500,000 patients are treated every year in France for the management of 80 severe and often rare pathologies.

The main subsidiaries are LFB Biomédicaments (France, Plasma derived products), LFB Biotechnologies (France, Biotech & R&D), GTC Biotherapeutics (USA, transgenics), MAbgène (Bioproduction – France), LFB hemoderivados e biotecnologia (Brazil).
Christian Béchon is the chairman and the CEO of LFB S.A.

2009 key figures:

• € 376 million in turnover
• 7% annual growth
• € 76 million dedicated to Research and Development
• 1700 total employees (1600 in France)

Merck & Co., Inc., Whitehouse Station, NJ, USA, is an innovative, global health care leader that is committed to improving health and well-being around the world. Merck discovers, develops, manufactures, and markets vaccines, medicines, and consumer and animal health products designed to help save and improve lives.
The recent merger of Merck and Schering-Plough greatly expands our combined company's product offerings in a range of areas, including heart and respiratory health, infectious diseases, and women’s health. We continue to focus our research on conditions that affect millions of people around the world — diseases such as Alzheimer’s, diabetes, and cancer — while expanding our strengths in areas like vaccines and biologics.
Merck invests heavily in research and development. Our strategy for growth is based on breakthrough research — both internal and external through partnerships — and demonstrating the value of our medicines to patients, payers, and providers.
At today’s Merck, we’re applying our global reach, financial strength and scientific excellence to do more of what we’re passionate about: improving health and improving lives. | More about | Website

Teva Pharmaceuticals Limited is one of the world’s top 20 pharmaceutical companies and is the leader in generic pharmaceuticals. Teva also has proprietary (or innovative) pharmaceuticals on the market and has a strong pipeline of innovative projects in clinical development.

Teva Innovative Ventures is seeking to increase further this Innovative pipeline by partnering or licensing pre-clinical programs via our flexible partnership models. We are looking for therapies for CNS disorders (with emphasis on neurology), auto-immune diseases, inflammatory diseases and oncology. Our key criteria are that the opportunities are at a development stage between lead molecule and first-in-man dosing, have strong IP, have efficacy demonstrated in an in-vivo animal model and that they can show differentiation from current clinical care.

We source novel programs from University groups, spin-out or start-up companies, and from smaller Biotech. We aim to rapidly develop our partners’ innovative therapies through our global development organisation, and make them available for patients. Teva currently operates in over 60 countries and has around 35,000 employees worldwide.

  Visit Sponsoring opportunities

Innovaro Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Innovaro Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world. Innovaro Pharmalicensing, and its newly launched sister service Innovaro Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 190,000 industry professionals each month. Innovaro Pharmalicensing is part of Innovaro Corporation, listed on AMEX (INV).

2 – 3 JUNE 2010

The Wellcome Trust Genome Campus, Cambridge The ERBI Conference brings together industry experts from major pharmaceutical companies, international investors and life science entrepreneurs.  The programme includes debates, discussions and presentations on key issues concerning the sector. Five reasons to register for the 2010 ERBI Conference: Attend the first event run by Europe’s first life science super cluster, formed bythe merger of ERBI and LBN Keynote presentations from global opinion leaders, including Professor Nina Fedoroff, advisor to the US Secretary of State, Professor Dame Julia Polak of Imperial College London and Professor Mike Stratton of the Wellcome Trust Sanger Institute Network with global businesses including GlaxoSmithKline, MedImmune, Merck & Co, Philips, Pfizer & Takeda Scheduled one-to-one partnering with potential business collaborators Interactive workshop on Stratified Medicine For further information please contact conference@erbi.co.uk or telephone, 01223 896 459. REGISTER NOW!   |   www.erbiconference.co.uk   |   Sinead Mullan - +44 1223 896459 – sineadmullan@erbi.co.uk